April 12, 2017 / 10:50 AM / 4 months ago

BRIEF-BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks

April 12 (Reuters) - BioCryst Pharmaceuticals Inc -

* BioCryst expands development of BCX7353 to explore treatment of acute HAE attacks

* Has received initial regulatory approvals in Europe to initiate zenith-1 exploratory clinical trial this summer

* To explore if single oral doses of liquid formulation of BCX7353 could have utility in treatment of acute angioedema attacks in some patients Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below